|Videos|July 23, 2021

First Vyluma product tackles pediatric myopia

Dive deep into Vyluma’s investigational atropine therapy. Navneet Puri, PhD, the company’s founder, chairman, and CEO, explains details of the clinical trials.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.


Latest CME